| Product name | E2F8 Polyclonal Antibody |
| Immunogen | Synthesized peptide derived from part region of human E2F8 protein |
| Host | Rabbit |
| Reactivity | Human,Rat,Mouse, |
| Applications | WB,ELISA |
| Applications notes | Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-2000;ELISA 1:5000-20000 |
| Clonality | Polyclonal |
| Preparation method | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Alternative | Transcription factor E2F8; E2F-8 |
| Formulation | Liquid solution |
| Concentration | 1 mg/ml |
| Molecular weight | 95kD |
| Storage buffer | PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA |
| Storage instructions | Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing. |
| Shipping | Gel pack with blue ice. |
| Precautions | The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product. |
| Background | E2F8 encodes a member of a family of transcription factors which regulate the expression of genes required for progression through the cell cycle. E2F Transcription Factor 8 regulates progression from G1 to S phase by ensuring the nucleus divides at the proper time. Multiple alternatively spliced variants, encoding the same protein, have been identified. |
| Gene ID | 79733 |
| Alternative | Transcription factor E2F8; E2F-8 |
| Others | The antibody detects endogenous levels of E2F8 protein |
| Accession | A0AVK6 |
| Observed Band(KD) | 95 |
You must be logged in to post a review.
Reviews
There are no reviews yet.